JP2018502089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502089A5 JP2018502089A5 JP2017533856A JP2017533856A JP2018502089A5 JP 2018502089 A5 JP2018502089 A5 JP 2018502089A5 JP 2017533856 A JP2017533856 A JP 2017533856A JP 2017533856 A JP2017533856 A JP 2017533856A JP 2018502089 A5 JP2018502089 A5 JP 2018502089A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096020P | 2014-12-23 | 2014-12-23 | |
| US62/096,020 | 2014-12-23 | ||
| PCT/US2015/067459 WO2016106357A1 (en) | 2014-12-23 | 2015-12-22 | Combination of raf inhibitors and aurora kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502089A JP2018502089A (ja) | 2018-01-25 |
| JP2018502089A5 true JP2018502089A5 (https=) | 2019-02-07 |
Family
ID=56151529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533856A Pending JP2018502089A (ja) | 2014-12-23 | 2015-12-22 | Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180263979A1 (https=) |
| EP (1) | EP3236948A4 (https=) |
| JP (1) | JP2018502089A (https=) |
| CN (1) | CN107205933A (https=) |
| CA (1) | CA2972076A1 (https=) |
| WO (1) | WO2016106357A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081585A1 (en) | 2016-10-28 | 2018-05-03 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
| CN111655228B (zh) | 2017-05-03 | 2024-02-09 | 听治疗有限责任公司 | 预防和治疗听力损失的组合物和方法 |
| WO2021108616A1 (en) * | 2019-11-27 | 2021-06-03 | Dot Therapeutics-1, Inc. | Solid dispersion of pan-raf kinase inhibitor |
| AU2021376286A1 (en) * | 2020-11-06 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Raf inhibitor for treating low grade glioma |
| CN116004567A (zh) * | 2022-12-07 | 2023-04-25 | 北京大学 | 极光激酶b基因k202突变及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747002B2 (en) * | 1999-05-11 | 2004-06-08 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US7666862B2 (en) * | 2003-08-15 | 2010-02-23 | Merck & Co., Inc. | Mitotic Kinesin Inhibitors |
| CN101056632B (zh) * | 2004-11-09 | 2011-12-07 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| DE602006014540D1 (en) * | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| AR067354A1 (es) * | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| ES2686549T3 (es) * | 2014-06-16 | 2018-10-18 | Worldwide Innovative Network | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer |
-
2015
- 2015-12-22 WO PCT/US2015/067459 patent/WO2016106357A1/en not_active Ceased
- 2015-12-22 EP EP15874329.4A patent/EP3236948A4/en not_active Withdrawn
- 2015-12-22 US US15/539,183 patent/US20180263979A1/en not_active Abandoned
- 2015-12-22 CA CA2972076A patent/CA2972076A1/en not_active Abandoned
- 2015-12-22 CN CN201580073520.8A patent/CN107205933A/zh active Pending
- 2015-12-22 JP JP2017533856A patent/JP2018502089A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502089A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| RU2622015C2 (ru) | Способ лечения пролиферативного заболевания | |
| JP2013507415A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP2020517696A5 (https=) | ||
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| WO2010129864A3 (en) | Methods and compositions for studying, imaging, and treating pain | |
| JP2015212268A5 (https=) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2011515397A5 (https=) | ||
| JP2018524347A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2009513662A5 (https=) | ||
| JP2019504068A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| JP2019510785A5 (https=) | ||
| JP2019525948A5 (https=) | ||
| JP2012522837A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| JP2019524888A5 (https=) | ||
| JP2019530711A5 (https=) |